Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Isotechnika -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (275)	5/13/2008 10:27:03 AM
From: teevee	Respond to of 285

tuck, The big driver for ISA which is not discussed in the RBC summary may be the licencing deal with Lux Biosciences. luxbio.com Lux working on a dry eye formulation based on ISA's voclosporin. They estimate between 15-20 million people in North America and Europe have the condition. Allergan currently projects 2008 sales of $400 million for their cyclosporin eye drops which cost patients about $100/month. Use is limited by eye irritation and side effects. If Lux's formulation doesn't irritate the eye and is efficaceous, the sales potential of say 10 million people at $100/month would be a block buster situation. Unfortunately, neither ISA or Lux provide details of the licencing agreement, so it is impossible to determine the potential size of the benefit to ISA. On another note, I wonder if ISA's fate will be that of Chugai and Genentech?